Georgia State University

ScholarWorks @ Georgia State University
Chemistry Theses

Department of Chemistry

8-8-2017

DNA Encoded Libraries (DEGL) of Glycan Antigens to Detect
Antibodies: An Approach Towards Next Generation Functional
Glycomics
Aishwarya Parameswaran
aparameswaran1@student.gsu.edu

Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_theses

Recommended Citation
Parameswaran, Aishwarya, "DNA Encoded Libraries (DEGL) of Glycan Antigens to Detect Antibodies: An
Approach Towards Next Generation Functional Glycomics." Thesis, Georgia State University, 2017.
doi: https://doi.org/10.57709/10453174

This Thesis is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia
State University. It has been accepted for inclusion in Chemistry Theses by an authorized administrator of
ScholarWorks @ Georgia State University. For more information, please contact scholarworks@gsu.edu.

DNA ENCODED LIBRARIES (DEGL) OF GLYCAN ANTIGENS TO DETECT
ANTIBODIES: AN APPROACH TOWARDS NEXT GENERATION FUNCTIONAL
GLYCOMICS

by

AISHWARYA PARAMESWARAN
Under the Direction of Peng George Wang, PhD
ABSTRACT
Structure and functional study of glycans are highly challenging due to the difficulties in
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application, by increasing the sensitivity of detection by polymerase chain reaction (PCR),
requiring minimal samples for analysis. Assuming bigger arena of DNA Encoded Glycan
Libraries (DEGL) in future, we propose here a method for uniquely coding all glycans using
computer program that can convert the structural information of glycans to DNA barcode. A
unique and universal coding for glycans will benefit both synthesis and analysis of DEGLs. As a
proof of principle study, a small DNA Encoded Glycan Library (DEGL) of blood and globo
series glycan antigen and its application was demonstrated in detecting blood group and breast
cancer from plasma.
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INTRODUCTION

Glycans are important biomolecules along with proteins, lipids, and nucleic acids. Glycans
can be divided into three main categories: O-linked glycans, N-linked glycans and glycolipids.2
Majority of glycans are made up of N-acetylglucosamine (GlcNAc), Glucose (Glc), Galactose
(Gal), Mannose (Man), N-acetylneuraminic acid (Neu5Ac), Fucose (Fuc), N-acetylgalactosamine
(GalNAc), Xylose (Xyl), Glucuronic acid (GlcA), Idose (Ido).1
Each cell in a multicellular organism is covered with dense and complex glycans. Most
cellular secretions and extracellular matrices are found to be high in glycans and glycosylated. It
is even seen that an envelope of a virus that bud from an infected cell to carry the glycosylation
pattern of the host cell.3
Glycans and glycoconjugates play a very important role in many areas of biological
processes including cell- cell interactions, pathogenicity, mediating immunological processes,
stabilizing proteins and cancer.4-6 Expression patterns of glycans are highly altered in diseases like
cancer, atherosclerosis, diabetes, retrovirus infection, thrombosis, arthritis, neurodegeneration and
many other diseases.8 Glycan structures are the important part of the antigenic determinants during
microbial infections to which the host immune cells recognizes and mount immune responses
against the infection.9 For example, breast cancer can be detected by Globo-H glycan, an important
biomarker seen in breast cancer.7 Therefore, glycans have a pivotal role in molecular recognition
and signaling, making sugar-receptor interaction at the structural level highly necessary; and this
interaction of polysaccharide with receptors are major area of focus in academic and industrial
research.8,10
Functional Glycomics; a systematic study of the structures and functions of carbohydrates
is yet to reach the level attained by the genomics and proteomics despite so much importance of
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glycans. Template driven biosynthesis of DNA-RNA-Protein by nature itself also known as the
Central Dogma Theory of Molecular Biology made the researchers apply and adopt this knowledge
in the synthesis and analysis of these molecules. Apart from this, the easy availability of
experimentation methods and materials for the synthesis and analysis of DNA, RNA, and proteins
made the researchers focus on genomics and proteomics and take up those areas to what they are
today. However, such free-flowing information is not available for carbohydrate making functional
glycomics exceptionally challenging. Since glycans are less organized without a template driven
machinery, it is necessary to develop a specific method for synthesis and analysis for each glycan.
Although with the recent advancement in technology allowed the development of solid phase
automated and enzymatic synthesis, which reduced the difficulties in obtaining the glycans, but
the materials and experimentations are still extremely difficult and complex especially for complex
glycans. Therefore, there is a need for a development of versatile and ultra-sensitive detection
technology as it is of high importance in the field of carbohydrate research for detection and
characterization of glycan-protein interaction.
The methods now used for studying glycan-protein interaction are mainly carbohydrate
microarrays,11,12 surface plasmon resonance,13 enzyme linked lectin assay,12 isothermal
calorimetry,14 glycosylated conductive polymer,15 and crystallographic studies.16 In carbohydrate
research, widely used method is microarray with carbohydrate derivatives by various means of
immobilization technology.11,17-18 However, all the above methods have its own limitations,
mainly because these techniques uses immobilized glycans that do not mimic the biological
environment of binding. The detection also requires tagging of the target, glycan modifications
and specific binding of antibodies, in addition, the interaction of glycans with targets are also very
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weak, which makes the generation sugar library having a glycodendrimer on a slide with optimum
distance for specific binding highly challenging.
DNA-encoded glycan libraries (DEGL) can be considered as a potential alternative or
adjunct to the prevailing glycan detecting techniques. DEGL adopt DNA sequences specifically
for each glycan in the library, which enable sensitive detection by signal amplification PCR and
identifying by DNA sequencing. For functional glycomics study, DEGL of interest is constructed
and interacted with specific proteins. Unbound glycans are removed by washing, and bound ones
are amplified using quantitative Polymerase Chain Reaction (qPCR), also known as real time PCR
(RT-PCR) and sequenced to reveal identities.
Next generation technologies in genomics extended the applications of DNA beyond
genetics, the most prominent one being DNA encoding. The concept of DNA encoding was
introduced in 1992, but it gained momentum recently with the advancement of Next Generation
Sequencing (NGS) technologies.20-22 The major advantage of the technology is its efficiency in
handling thousands of molecules with uniquely generated sequences and their high throughput
analysis. The DNA tagging concept was initially applied in glycomics by Kwon and his coworkers,
demonstrating Glyco-PCR, a method to detect Glycan-Binding Proteins (GBP) using DNAconjugated glycan with high sensitivity. 23-24 In one of the previous work reported by Kwon and
his coworkers, they have shown glyco-quantitative polymerase chain reaction (Glyco-qPCR) assay
platform that allows the ultrasensitive detection and quantification of glycan in biological samples.
They used therapeutic carbohydrates like chondroitin sulfate (a GAG), and Proteoglycans (PG)
from Chinese hamster ovary cells (CHO) separated by capillary electrophoresis, Glycoprotein
obtained from PNGaseF treatment of decorin core Glycoprotein (GP). They used EDC/NHS
chemistry to covalently link the DNA tag and glycan, and unbound DNA was washed using
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streptavidin-coated magnetic beads as the glycans they used were biotinylated. They also did a
proof of concept study, in GAG-binding proteins, where interaction was tested between HeparinAntithrombin and Chondroitin-Antithrombin. With this work, they proved that glyco-qPCR can
be used to analyze the glyco-interactome and by applying PCR amplification glycan as low as 1
zettamoles can be detected.23
Later on, they also demonstrated glyco-PCR in the detection of active botulinum
neurotoxin (BoNT). They used Sialyllactose, which interacts with binding-domain of BoNTs,
sialyllactose-DNA conjugate was used as binding-probe for active BoNT and recovered through
BoNT-immunoprecipitation. Glyco-PCR analysis of the bound sialyllactose-DNA is then used to
detect low attomolar concentrations of BoNT and attomolar to femtomolar concentrations of
BoNT in honey. They also did a comparative study through the dual binding of antibodies and
monovalent or multivalent SL-DNA conjugates to toxins.24
But these studies were limited to certain types of glycan and there was no rationale behind
the selection of DNA sequences. Thus, developing a general platform for the DNA encoding of
glycans and subsequent detection has a significance role to play in the functional glycomics. In
this work, we demonstrated three fundamental aspects of DNA encoding of glycans, a universal
methodology for the coding of glycans based on the structure of the glycan, an easy and efficient
chemistry for the coupling of the DNA with the glycan and finally PCR and qPCR-based methods
for the quantitative detection of the glycans.
1.1

Purpose of the Study
Glycans play a very important role in many biological processes including cell- cell

responses, pathogenicity and immune responses etc. Despite so much importance, there is still a
need for an efficient method for detection and analyzing glycan-protein interactions in the field of
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carbohydrate research. Currently, carbohydrate microarray is successfully being used with the
help of immobilization technology. But this also has its own limitations, most important one is its
efficiency of mimicking the biological environment of the binding. Hence, we envision here
developing a successful method for DNA-encoded Glycan Libraries (DEGLs).
There has already been reported evidence,23-24 for demonstrating Glyco-PCR, as a method
to detect Glycan- Binding Protein (GBP). But these studies do not have any rationale behind the
selection of DNA tags. Our aim is to develop a broadly accepted general platform for DNA
encoding in glycomics. This could be achieved by proper selection of DNA codes, DNA-Glycan
conjugation by click chemistry and method of detection of DNA-Glycan conjugates using qPCR.
This work attempted to address all three steps generating a DNA code specifically for each
glycan by a developing a software, which could be used in future for any DEGL containing any
specific glycans, generation of DNA tags for each element in the library by adding forward and
reverse primer binding on each end for PCR amplification, and 5’ terminal alkyne modification to
offer coupling with the glycan using click chemistry (CuAAC) and to develop a method of
detection of DNA-Glycan conjugates using qPCR as a proof principle application study.
Generating a DNA code specific for each glycan-based on its structure was attained by
developing a software using basic computing principles in a computer language Python. The
development and the logic underlying in generating a DNA code specific for each glycan is
described elaborately under experiment section later.
1.1.1 Click Chemistry
Lack of abundant samples to play with demands a near perfect conjugation chemistry for
the synthesis of DNA glycan conjugates. We tested few of the well-known bioorthogonal reactions
widely used in chemical biology, glycan analysis and detection many cell surface glycans.25-26
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Well developed bioorthogonal reactions include Staudinger Ligation, 27 Copper-catalyzed azidealkyne Cycloaddition (also called as CuAAC),28 strain promoted alkyne-azide cycloaddition (also
called as Cu-free click chemistry or SPAAC).29

Figure 1.1 Staudigner Ligation
Staudinger ligation was the first bioorthogonal reaction reported by Staudinger and coworkers in 1919.27 This is bioorthogonal ligation that transforms azides to primary amines by
phosphines.30 Later some modifications were made to this reaction, such as using modified
reagent. Accompanied by those changes, Staudinger ligation suffered from slow kinetics and easily
oxidized phosphine reagents during the reaction process, thus making the reaction not a perfect
candidate for glycan analysis and detection.31
The most popular and common bioorthogonal method is copper-catalyzed click
chemistry.28,32 This is a copper- catalyzed cycloaddition between alkyne and azide to form a 5
membered ring.33 In early 2000’s, Sharpless group and Meldel group discovered that this reaction
could be accelerated by copper dramatically, and this reaction can take place in an aqueous
system.27,31 This copper- catalyzed azide-alkyne cycloaddition (CuAAC) is used widely in
chemical biology, cell biology, cell surface glycan analysis and detection. This reaction being very
simple and easy to perform it is widely been used by researchers both in industry and academia.
During our study, we found most satisfying results with the click reactions and we adopted this
chemistry for all our future work.
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Figure 1.2 Copper-Catalyzed Click Chemistry (CuAAC)
1.1.2 PCR
Another important part of our study is PCR, which is highly essential for the detection of
DNA that is coupled with glycan which in turn symbolizes the glycan presence. The advent of the
Polymerase Chain Reaction (PCR) radically transformed biological science from the time it was
first discovered by Mullis in 1990. PCR based strategies have propelled huge scientific endeavors
such as Human Genome Project. The technique is currently used by clinicians and researchers to
diagnose diseases, clone and sequence genes, and carry out sophisticated quantitative and genomic
studies in rapid and very sensitive manner. One of the most important medical applications of PCR
method is the detection of pathogens. In addition, it is also widely used in forensics for the
identification of criminals.46
PCR can be performed using source DNA from a variety of tissues and organisms,
including peripheral blood, skin, hair, saliva, and microbes. Only trace amounts of DNA are
needed for PCR to generate enough copies to be analyzed using conventional laboratory methods.
For this reason, PCR is a sensitive assay. Each PCR assay requires the presence of template DNA,
primers, nucleotides, and DNA polymerase. The DNA polymerase is the key enzyme that links
individual nucleotides together to form the PCR product. The nucleotides include the four bases –
adenine, thymine, cytosine, and guanine (A, T, C, G) – that are found in DNA. These act as the
building blocks that are used by the DNA polymerase to create the resultant PCR product. The
primers in the reaction specify the exact DNA product to be amplified. The primers are short DNA
fragments with a defined sequence complementary to the target DNA that is to be detected and
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amplified. These serve as an extension point for the DNA polymerase to build on. The abovementioned components are mixed in a test tube or 96-well plate and then placed in a thermal cycler
that allows repeated cycles of DNA amplification to occur in three basic steps. The reaction
solution is first heated above the melting point of the two complementary DNA strands of the
target DNA, which allows the strands to separate, a process called denaturation. The temperature
is then lowered to allow the specific primers to bind to the target DNA segments, a process known
as hybridization or annealing. Annealing between primers and the target DNA occurs only if they
are complementary in sequence (e.g. A binding to G). The temperature is raised again, at which
time the DNA polymerase is able to extend the primers by adding nucleotides to the developing
DNA strand. With each repetition of these three steps, the number of copied DNA molecules
increases exponentially.46 The PCR product is analyzed using agarose gel electrophoresis, which
separates the DNA product based on the size and charge. The two main methods used for
visualization of DNA are staining the product using ethidium bromide dye, which intercalates
between the two strands of the DNA. However, due to the prevailing carcinogenic and serious
health effects of ethidium bromide, it’s use has been reduced and replaced by SYBR™, a safe
DNA gel stain.

Figure 1.3 Key Components Of PCR
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1) Denaturation: the reaction is heated to 95oC-98oC for 20-30 secs to break the hydrogen bonds; 2)
Annealing: The reaction temperature is lowered to 50oC- 65oC for 20-40 secs (preferably 2oC-4oC less than
the Tm of primers) to allow the primers to anneal to the template strands; 3) Elongation: The temperature
is increased (optimum temperature of DNA polymerase preferably 72oC-78oC) to allow the addition of
dNTP’s. At end of each cycle, the target sequence is doubled.

The next generation advancement of the PCR technology was the development of RTqPCR. While in end point, PCR requires that PCR products were detected and quantified by gel
electrophoresis after completion of the reaction, real-time qPCR technology allows quantification
of PCR products in “real time” during each PCR cycle, yielding a quantitative measurement of
PCR products accumulated during the course of the reaction. Real-time reactions are carried out
in a thermocycler that permits measurement of a fluorescent detector molecule, which decreases
post-processing steps and minimizes experimental error. This is most commonly achieved through
the use of fluorescence based technologies. Three main fluorescence based technologies are, probe
sequences that fluoresce upon (i) hydrolysis (TaqMan; Applied Biosystems, Foster City, CA,
USA) or hybridization (LightCycler; Roche, Indianapolis, IN, USA); (ii) fluorescent hairpins; or
(iii) intercalating dyes (SYBR Green). As SYBR™ Green binding is not specific for a target
sequence this system can be readily used for different gene assays, is flexible, inexpensive, and
accurate results can be obtained provided validation of the specificity by melt curve (or
dissociation curve) analysis. The TaqMan™ chemistry is more expensive than DNA binding dye
assays, but the presence of the hydrolysis probe ensures that only specific amplicons are measured.
In addition, multiplexing reactions are possible, although their set-up requires an important
optimization phase.47,48
In brief, similar to end-point PCR, qPCR consists a succession of amplification cycles in
which the template nucleic acid is denatured, annealed with specific oligonucleotide primers, and
extended to generate a complementary strand using a thermostable DNA polymerase. This results
in an exponential increase of amplicons (amplification products) that, in contrast with end-point
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PCR, can be monitored at every cycle (in real time) using a fluorescent reporter. The increase in
fluorescence is plotted against the cycle number to generate the amplification curve, from which a
quantification cycle Cq (often described as Ct for cycle threshold) value can be determined. Cq
corresponds to the number of cycles for which the amount of fluorescence (hence, of the template)
is significantly higher than the background fluorescence. Therefore, the Cq value can be linked to
the initial concentration of target nucleic acid and serves as a basis for absolute or relative template
quantification. All steps of (RT-)qPCR may introduce experimental errors. qPCR is a robust
technique, but due to its high sensitivity, very small variations can induce non-negligible
differences in the results. To measure intra-assay variability, which follows a statistical
distribution, RT-qPCR can be performed in triplicate (experimental replicates). Inter-assay
variability can be estimated using a “reference” sample that will be included in each experiment.48

Figure 1.4 Phases of qPCR.
The PCR process goes through three main phases as the number of cycles and the amount of product
generated increase. Initially, when the amount of product is small and enzyme and reagents are not limiting,
product generation is exponential and the reaction is closest to 100% efficiency. This exponential growth
is hard to detect initially through real-time fluorescence because the amount of product is small. During
the linear phase, products continue to accumulate, but the reaction efficiency begins to fall and reagents
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become limiting. Finally, in the plateau phase of the reaction, accumulation of product ceases as the
reaction is exhausted for a number of different reasons.47

For overall method development we adopted two systems, initially, we used the most
known blood glycan antibody system (ABO) for the early stage method optimizations and, later
we used the Globo-series glycan analogs as a small DNA encoded library for the proof of principle
demonstration via detecting the breast cancer from patient plasma.
1.1.3 ABO Blood Group System
The discovery of the ABO blood group, over 100 years ago, caused great excitement. Until
then, all blood had been assumed to be the same, and the often-tragic consequences of blood
transfusions were not understood. The modern basis of the ABO blood group system was coined
by Karl Landsteiner in 1900 when he discovered that the blood group of certain people
agglutinated red cells present in other individuals.34 Ever since it has been studied extensively and
well characterized with the structures of antigens and antibodies involved. The terminal
carbohydrate structures present on the red blood cells and their antibodies present in the blood
plasma determine the blood group.
The ABO blood group antigens remain of prime importance in transfusion medicine— they
are the most immunogenic of all the blood group antigens. The ABO blood group antigens also
appear to have been important throughout our evolution because the frequencies of different ABO
blood types vary among different populations, suggesting that a particular blood type conferred a
selection advantage (e.g., resistance against an infectious disease.)
The ABO blood group antigens are encoded by one genetic locus, the ABO locus, which
has three alternative (allelic) forms—A, B, and O. A child receives one of the three alleles from
each parent, giving rise to six possible genotypes and four possible blood types (phenotypes).
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Table 1.1 Possible Blood types in offsprings
ABO Alleles Inherited from Mother
ABO
Alleles
A
B
O
Inherited
from A
A
AB
A
Father
B
AB
B
B
O
A
B
O
The four basic ABO phenotypes are O, A, B, and AB. After it was found that blood group
A RBCs reacted differently to a particular antibody (later called anti-A1), the blood group was
divided into two phenotypes, A1 and A2. RBCs with the A1 phenotype react with anti-A1 and
makeup about 80% of blood type A. RBCs with the A2 phenotype do not react with anti-A1 and
they make up about 20% of blood type A. A1 red cells express about 5 times more A antigen than
A2 red cells, but both types of red cell react with anti-A, and A1 and A2 blood groups are
interchangeable.
The immune system forms antibodies against whichever ABO blood group antigens are
not found on the individual's RBCs. Thus, a group A individual will have anti-B antibodies and a
group B individual will have anti-A antibodies. Blood group O is common, and individuals with
this blood type will have both anti-A and anti-B in their serum. Blood group AB is the least
common, and these individuals will have neither anti-A nor anti-B in their serum.
Table 1.2 Antibodies and Antigen present in ABO Blood Typing System
RBC of
different blood
group

Antibodies in
Serum
Antigen in RBC
A
surface
Genotype
AO or AA

None
B

A and B

None

BO or BB

AB

OO
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The ABO locus is located on chromosome 9 has three main allelic forms: A, B, and O. The
A allele encodes for a glycosyltransferase that produces the A antigen (N-acetylgalactosamine is
its immunodominant sugar), and the B allele encodes for a glycosyltransferase that creates the B
antigen (D-galactose is its immunodominant sugar). The O allele encodes for an enzyme with no
function, and therefore neither A or B antigen is produced, leaving the underlying precursor (the
H antigen) unchanged. These antigens are incorporated into one of four types of oligosaccharide
chain, type 2 being the most common in the antigen-carrying molecules in RBC membranes.

Figure 1.5 ABO Blood antigen structures.
For A/B antigen synthesis to occur, a precursor called the H antigen must be present. In
RBCs, the enzyme that synthesizes the H antigen is encoded by the H locus (FUT1). In saliva and
other bodily secretions, the enzyme that synthesizes the H antigen is encoded by the Se locus
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(FUT2). The H locus is located on chromosome 19 and it encodes a fucosyltransferase that
produces the H antigen on RBCs.49
Table 1.3 Distribution of various Blood Groups among Population
Population Blood
Blood
Blood
Blood
Blood
Group
Group
Group
Group
Group
‘O’
‘A1’
‘A2’
‘B”
‘A1B’
Caucasians 44%
33%
10%
9%
3%
Africans
49%
19%
8%
20%
3%
Asians
43%
27%
Rare
25%
5%
1.1.4

Blood
Group
‘A2B’
1%
1%
Rare

Globo-H

Similarly, eukaryotic cells are covered by a glycocalyx: an extensive network of
polysaccharides. The glycocalyx serves as a rich source of binding sites for receptors and ligands,
as well as pathogens and toxins. The mammalian glycome is estimated to consist of a few hundred
unique glycan structures on glycoproteins and glycolipids. One such glycan is Globo H.50
Some of the Globo-series glycans are overexpressed in certain cancers and are proven as
biomarkers for early detection of breast cancer and ovarian cancer.7,35-37 Recent developments in
the Globo-H immunotherapy also needs high sensitive methods to quantitatively detect the
antiglobo-H antibodies for monitoring the therapy and in clinical trials.38-40
Globo H is a glycosphingolipid of the Globo series with a sugar terminus resembling the
blood group antigen H determinant. First identified in human teratocarcinoma and breast cancer
cells, Globo H was found to be overexpressed on the cell surface of several epithelial cancers such
as breast, colon, endometrial, gastric, pancreatic, lung, and prostate cancers. It is also moderately
expressed in normal epithelial tissues (lung, breast, prostate, stomach, pancreas, and ovary), but
its distribution is restricted to apical epithelial cells at lumen borders.36 In breast cancer Globo H
expression was observed in >60% of ductal, lobular, and tubular carcinoma, but not in
nonepithelial breast tumors. Globo H is not expressed in normal tissue except for weak expression
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in the apical epithelial cells at lumen borders, a site that appears to be inaccessible to the immune
system. Thus, Globo H has been considered as an ideal target for immunotherapy of many
epithelial cancers and indeed two phase I trials of a Globo H-based vaccine in breast and prostate
cancer, respectively, have shown promising results.45
Functionally, Globo H has been associated with tumor stem cells, to be a potent inducer of
angiogenesis, and an immunosuppressor through Notch signaling. The high Globo H expression
by only cancer and cancer stem cells made it an attractive target for the generation of therapeutic
cancer vaccines. These vaccines underwent the long history of development and improvement and
are currently being tested in clinical trials for treatment. Globo H has therefore been considered as
one promising tumor associated glycan biomarker, in particular for breast cancer.36

Figure 1.6 Globo-H Structure
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2
2.1

EXPERIMENT

Systematic Coding of Sugars
The first aim was to develop a unique coding method that is consistent with the

representation of glycans, so it can be used in future for any DEGL with ease and without any
uncertainty in future glycomics. Unlike peptides, proteins and DNA/RNA, representation of
carbohydrate brings many challenges. A detailed representation should feature composition,
sequence, branching position, modifications, and anomeric configuration. The use of symbols to
represent the glycans was first proposed by Kornfield et.al.41 This approach has replaced the use
of IUPAC naming for representation of glycan, with modifications adapted timely to fit the entire
glycome.42-43 All these representations are based on symbols and color codes to represent the
building blocks.
Table 2.1 Glycan Representation (CFG)
Symbolic Representation (Cartoon Representation
IUPAC Naming (Linear Code)
CFG)
GalNAc b1-4 (Fuc a1-2) GlcNAc b14 Man a1-3 (GalNAc b1-4 (Fuc a1-2)
GlcNAc b1-4 Man a1-6) Man b14 GlcNAc b1-4 (Fuc a1-6) GlcNAc

With the above approach, it is pragmatic to use nucleotide bases to represent the glycans.
But this also brings prevailing challenges for using nucleotide bases for glycans as there are many
symbols and color codes are available for representation, but there are only 4 nucleotides bases A,
T, G, and C are available for coding. To have enough nucleotide codes to cover the entire the
glycome we had to depend on permutation and combination approach. There are many sugar
monomers which are incorporated in many ways in a glycan, making glycan structural information
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very complex. These inherit difficulties lead to the development of a dedicated computer program,
which can manage the structural information of the glycan to coding dictionaries and transform
the IUPAC name of glycan to single stranded DNA code. For easy acceptance of the codes, the
codes should be of minimal length storing all the glycan information and enable both PCR and
qPCR amplification.
For a perfect structure based coding, there must be a controlled vocabulary for all the
structural components. For attaining this goal, the structural components of the carbohydrate were
split into the structural components monosaccharides, linkages, and modifications etc. Three
independent libraries were generated namely library A for monomer, library B for linkage and
library C for modification. Next, all the monomers were gathered in library A and assigned each
one with unique four-letter code. There are about 256 combinations generated using A, T, G, and
C. About 70 monomers are added to this library as of now using the randomly generated codes. In
a similar way, all possible linkages were accounted for library B, using codes based on 3 letters.
Currently, there are 36 linkages in this library. For library C about 100 modifications were
identified and incorporated in the library C and assigned with 4 letter codes which were not used
in the library A. Special characters like ‘(` in the IUPAC naming for branching were assigned
special codes. All these libraries were then incorporated into a Python-based program and the
program was tested for about 100 glycans, for which the program successfully delivered the codes.
The libraries can be extended and modified for addition as and when needed, to make this program
a universal one and available for research community.
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Table 2.2 Glycan Representation with DNA Codes
DNA
Code
(Cartoon IUPAC
Naming
obtained through
(Linear Code)
the program
GalNAc b1-4 (Fuc a1- ACGCTGTTTT
2) GlcNAc
b1-4 AGAAAAGAA
Man a1-3
AAAGCTGTAA
(GalNAc b1-4
TAAACTTTAC
(Fuc a1-2)
GCTGTTTTAG
GlcNAc b1-4 Man a1- AAAAGAAAA
6)
Man b1- AGCTGTAATA
4 GlcNAc b1-4
ACAAAAAAT
(Fuc a1-6) GlcNAc
ATGTAAGCTG
A sequence length between 50 -100 is best for PCR applications. TTTTAGAAAC
Among 100 glycans
AAAAAAGC
tested most fell within this limit, but some exceeded this. Through careful observation of the
Symbolic
Representation
Representation CFG)

sample library, there were many repeating fragments in the glycans (e.g. Six sugar core of Nglycans). Hence, by taking this as a single block would reduce the length overall length of the
codes of the long glycans, so a fourth library (Library D) was included in the program containing
most of the common building blocks found in the glycans. Similar to other libraries, library D can
also be extended, so as to cover the entire glycome and make it a universal one.
Table 2.3 Long and Short DNA codes of the Glycan
Short
DNA
Code
IUPAC Naming (Linear Long DNA Code obtained through
obtained through the
Code)
the program
program
GalNAc b1-4 (Fuc a1- ACGCTGTTTTAGAAAAGAAA ACGCTGTTTTAGAAA
2) GlcNAc b1-4 Man a1-3 AAGCTGTAATAAACTTTACG AGAAAAAGCTGTAA
(GalNAc b1-4 (Fuc a1-2) CTGTTTTAGAAAAGAAAAAG TAAACTTTACGCTGT
GlcNAc b1-4 Man a1-6)
CTGTAATAACAAAAAATATG TTTAGAAAAGAAAA
Man b1-4 GlcNAc b1-4
TAAGCTGTTTTAGAAACAAA AGCTGTAATAACAA
(Fuc a1-6) GlcNAc
AAAGC
AAGTACA
Length – 105
Length - 79
Another probable issue encountered was with short glycans, which gives small codes of
length less than 25. This will face practical difficulty while doing qPCR. To resolve this issue a
random DNA sequence of length 20 was added to the code with a mention in the program to avoid
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the misreading. These two modifications made sure to keep the sequences within the desired limits
to be used in the qPCR.
Table 2.4 DNA code for short glycans
IUPAC
Code)

Naming

Rha

2.2

Expanded DNA Code
(Linear DNA Code obtained through
obtained
through
the
the program
program
ATAG
ATAGCCCCAGTCAGGC
Length – 4
CTAACGTA
Length - 24

Coding and Decoding of glycans through Program
2.2.1

Coding

For getting nucleotide sequence, glycan sequence is given in the input box with spaces in
between each character of the glycan sequence. When a glycan sequence is inputted the program
looks for each character from left to right. It checks for match in monomer dictionary (Library A),
linkage dictionary (Library B) and modification dictionary (Library C). If a match is found, the
corresponding nucleotide is placed under the name ‘nuc’.
If the length of the nucleotide is less than 20, then an R nucleotide sequence is added to the
‘nuc’ to increase the length the nucleotide sequence and output is published.
If length of ‘nuc’ is more than 20 then the whole length of ‘nuc’ is searched for any
matching sequences in the core dictionary (Library D). If there is match then a lengthy nucleotide
core is replaced by a short 5 length sequence. This is done to reduce a lengthy nucleotide to short
one for cost effectiveness. Reduced ‘nuc’ output is published.
2.2.2

Decoding

For decoding the nucleotide sequence back to glycan sequence, in the input box nucleotide
sequence is given. The nucleotide sequence is searched for any matching five-length sequences in
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the core dictionary (Library D). If there is any matching sequence then the length of nucleotide is
extended to the original lengthy nucleotide sequence.

Figure 2.1 Flowchart describing Coding

If length of nucleotide is more than 0; first four nucleotide sequence are taken and match
is found in the carb dictionary (Library A) and corresponding carb is taken for the output. Next
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three nucleotide sequences are taken and searched for a match in linkage dictionary (Library B);
if there are no match then next four nucleotides are taken and searched in modification dictionary
(Library C) and next three nucleotides are again searched for a match in linkage dictionary (Library
C). Then next three nucleotides are taken and seen if it is ‘AAA’ or ‘TTT’, if it is so then a
corresponding branching is taken for output. Then next three nucleotides are taken and seen if it is
‘AAA’ or ‘TTT’, if it is so then a corresponding branching is taken for output. This is done to
cover the double branching cases. This continues for the complete length of the nucleotide
sequence, before publishing the output.

Figure 2.2 Flowchart describing decoding
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Figure 2.3 CFG representation and DNA code for blood antigen A
2.3

Materials
All chemicals and biological reagents were purchased from Thermo Fisher unless

otherwise mentioned. Maxima SYBR Green/ROX qPCR Master Mix, Platinum Pfx DNA
Polymerase were purchased from Life Technologies (Carlsbad, CA). Micro Bio-Gel P-30
Chromatography Columns were purchased from Bio-Rad (Hercules, CA). Tris[(1-Benzyl-1H1,2,3-Triazol-4-yl) methyl] amine (TBTA) Click chemistry Ligand were purchased from TCl
(Tokyo, Japan). MicroAmp 96 well Fast PCR Reaction Plate, MicroAmp Optical Adhesive Film,
MicroAmp Fast Reaction Tubes, Strips were purchased from Applied Biosystems (Foster City,
CA). All oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA).
Blood Group A Antigen-Antibody HE-193 (MA1-19693), Blood Group B Antigen-Antibody
HEB-29 (MA1-19691) and Blood Group ABH Antigen-Antibody HE-10 (MA1-19694) were
purchased from Thermo Fisher.
2.4

Gradient PCR and Tm Determination
Gradient PCR was performed to figure out the optimal melting temperature to be used in

the further quantitation experiments. Platinum Pfx DNA Polymerase was used for the PCR,
approximately 26 µg of template, 1 µL of primers (10 µM), 1mM dNTP, 10X amplifying buffer,
MgSO4, Polymerase and nuclease free water was used for a typical 25 µL reaction. Standard
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thermocycling condition were used with different temperature during annealing phase of the cycle
(95°C for 10 min, X°C for 30s, 95°C for 15s, 13 cycles) wherein X represents the annealing phase
and temperature gradient from 50 oC - 60 oC were tested during this phase. The amplified PCR
products were analyzed using 4% agarose gel electrophoresis. Tm determined using this method
was used for qPCR.
Table 2.5 Reaction mix for gradient PCR
Component
25 uL
50 uL Final
Concentration
10X
Amplifying 5 uL
10 uL Buffer
MgSO4
1 uL
2 uL
dNTP(10mM)
0.75 uL 1.5 uL 0.3mM
Forward
0.75 uL 1.5 uL 0.3uM
Primer(10uM)
Reverse
0.75 uL 1.5 uL 0.3uM
Primer(10uM)
Template(1uM)
1 uL
2 uL
0.04
Polymerase
0.3 uL
0.5 uL Nuclease-Free Water 15.4 uL 31 uL 2.5

Synthesis of Glycan(Antigen) – DNA Conjugates
Glycan(Antigen)- DNA Conjugates were synthesized using Azido-Alkyne cycloaddition

click reaction. The 5’-/5Hexynyl-terminated DNA was procured from the commercial suppliers
(IDT) with standard desalting purified. All glycans were synthesized via chemo enzymatic method
with the azido propyl linker at the reducing end.
2.5.1

Click reaction procedure

5’-Hexynyl-terminated DNA (500µM,20 µL, final concentration of 50 µM), azido glycan
(500µM, 30 µL, final concentration of 75µM), 2M TEA buffer (pH 7, 20 µL, final concentration
of 0.2M), 5 mM of freshly prepared Ascorbic acid solution (20 µL, final concentration 0.5mM),
10 mM of copper-TBTA in 55% DMSO (10 µl, final concentration 0.5 mM) and 50 % volume
DMSO (100 µL) were mixed together in a tube. The reaction mixture was vortexed and kept at
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room temperature for overnight. The reaction mixture was purified using Micro Bio-Gel P-30
Chromatography Columns (20 base pair cut-off). The concentration of the Glycan (Antigen)-DNA
Conjugates was determined by absorbance at 260/280 using Nanodrop (ThermoFisher).

Figure 2.4 Click Conjugation of 5’-Hexynyl DNA and azido modified glycans
2.6

General protocol for qPCR
2.6.1

For a typical 12.5 µL reaction

The glycan(Antigen)- DNA Conjugates were added to 6.25 µL 2X Maxima SYBR Green/
ROX qPCR Master Mix with 1 µL primers (Forward Primer – 500 nm and Reverse Primer- 300
nm). qPCR was performed with Applied Biosystems Stepone System (50 oC for 2 mins (Holding),
95oC for 10 mins (Holding), 95 oC for 15 s, 60oC for 10 s, 72 OC for 10 s for 40 cycles).
Ct or threshold cycle is a measurement of signal intensity for qPCR experiments. In a qPCR
experiment, PCR is performed in presence of a fluorogenic intercalating dye (SYBR Green in our
case). The dye intercalates with double-stranded DNA, as more double-stranded DNA is produced
in each PCR cycle the dye increases the fluorescence intensity. Once the fluorescence intensity
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reaches a threshold level, the cycle number is recorded by the instrument as Ct value. Therefore,
sample having a large amount of DNA will have a lower Ct value compared to those samples
containing relatively less amount of DNA.
Table 2.6 Reaction mix for qPCR
Component
Volume (in uL)
2x Maxima SYBR Green/ROX qPCR 6.25
Master Mix
Forward Primer(500nm)
1
Reverse Primer(300nm)
1
Template (Gradient as stated above)
1
Nuclease Free Water
3.25
2.7

Filtration of Antibody-Antigen DNA Conjugates
10 µL of glycan(antigen)-DNA Conjugate (5 µM) was incubated with 2 µL of antibody (if

plasma is used then 2 µL of plasma is diluted to 8 µL using water) for 2 hours at room temperature.
After two hours, the reaction volume was made up to 100 µL using TBST buffer. The reaction
solution was washed using 100 µL TBST buffer for 7 times in 100kda cutoff centrifugation
filtration filter tubes at 5000g for 10 mins. After washing the filtered and concentrated solution
was used as a template for qPCR analysis.
2.8

Immunoprecipitation of Antibody-Antigen-DNA Conjugates
10 µL of glycan(antigen)- DNA Conjugate (5 µM) was incubated with 2 µL of antibody

(if plasma is used then 2 µL of plasma is diluted to 8 µL using water) for 2 hours at room
temperature. After two hours, the reaction volume was made up to 100 µL using TBST buffer and
added to 20 µL of prewashed A/G protein bead and incubated for one hour at room temperature
with occasional shaking at an interval of 15 mins. After one hour, the beads were washed
thoroughly for 7 times using TBST buffer. After washing the beads were reconstituted in 20 µL of
TBST buffer. The beads were directly used a template for qPCR analysis.
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2.9

Blood Collection
Blood was collected from 10 volunteers by finger pricking, and collected to heparin-coated

blood collection tubes. The collected blood was centrifuged at 5000 rpm for about 5 mins for
obtaining plasma from blood. The collected plasma is stored at -20oC until use.
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3

RESULTS AND DISSCUSSION

In this study, I have developed a program which can generate DNA code specifically for
each glycan (described in systematic coding of sugars under experimental section). Next steps
were to successfully couple DNA and glycan using click chemistry, develop methods for glycan
and protein binding, and analyze the glycan using qPCR.
3.1

DNA sequences
Using the developed Python-based program DNA sequences for blood group antigens and

Globo glycan series were obtained.
Table 3.1 DNA sequences
For all 5’ to 3’ DNA Sequences BOLD is the forward primer and BOLD ITALIC is the reverse primer
binding site.

Name
O DNA

5’Mod
5Hexynyl

A DNA

5Hexynyl

B DNA

5Hexynyl

Gb-H

5Hexynyl

Gb-5

5Hexynyl

Gb-4

5Hexynyl

Gb-3

5Hexynyl

Gb-2

5Hexynyl

Bb-4

5Hexynyl

Bb-3

5Hexynyl

Bb-2

5Hexynyl

FW Primer
RV Primer

None
None

Sequence
AATGATACGGCGACCACCGAAGAAAAGACGATCTAAGCTCT
ACGATGTAAGACACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAACGCAACTTTAGAAAAGAAAA
CGATCTAAGATCTACGATGTAACACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAACGAAACTTTAGAAAAGAAAA
CGATCTAAGCTCTACGATGTAAGACACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAAAGAAAAGACGATCTACGCTC
TACGAATAACGATGTAAGACACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAAACGATCTACGCTCTACGAATA
ACGATGTAAGA CACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAACGCTCTACGAATAACGATGTA
AGACACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAAACGAATAACGATGTAAGACC
CCAGTCAGGCCTAACGTACACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAAACGATGTAAGACCCCAGTCA
GGCCTAACGTA CACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAAAGAAAAGACGATCTACGCTC
TACGACACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAAAGAAAAGACGATCTACGCCC
CCAGTCAGGCCTAACGTACACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAAAGAAAAGACGACCCCAGTCA
GGCCTAACGTACACGTCTGAACTCCAGTCAC
AATGATACGGCGACCACCGAA
GTGACTGGAGTTCAGACGTG

3’Mod
None
None
None
None
None
None
None
None
None
None
None
None
None
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The obtained DNA sequences were flanked with primer binding domains and 5’ Hexynyl
modification were procured from IDT.
3.2

Tm Determination
Tm was determined using the protocol for gradient PCR and Tm Determination (under

experimental section) for further quantitation experiments. After PCR to determine the optimum
temperature the PCR products were analyzed in using 4% agarose gel.

Figure 3.1 Tm Determination
Gel analysis of the PCR product (Figure 3.1) showed the optimum temperature to be in a
range of 52oC-60oC. 60oC was used as annealing temperature for further experiments.
3.3

Glycan (Antigen) – DNA Conjugates
After Tm determination, the 5’-Hexynyl terminated DNA and azido glycan were coupled

together using click chemistry according to the protocol mentioned under synthesis of
Glycan(Antigen) – DNA Conjugates (under experimental section).
A PCR comparison was conducted between pure DNA and G+DNA to make sure that the
DNA can be used for further PCR reaction after conjugation with glycan. PCR was conducted
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under the same conditions as stated under Gradient PCR and Tm Determination and analyzed using
4% agarose gel electrophoresis.

Figure 3.2 PCR Comparison of DNA_A and G+DNA_A
From the gel analysis of the PCR product (Figure 3.2) a clear concrete band was visible in
both DNA and G+DNA, which made sure that the DNA can be used for the further analysis after
conjugation with the glycan.
To make sure that the Glycan-DNA conjugate can be used for binding the protein with the
glycan and DNA can be used for PCR analysis, any presence of residual unreacted DNA was
further tested by PCR amplification and gel electrophoresis. Pure DNA_A and G+DNA_A was
incubated with the specific antibody for two hours and washed with the washing buffer, and later
eluted with the elution buffer. Both wash and elution buffers were collected and performed a PCR.
Gel analysis of the PCR product (Figure 3.3) did not show a band in the wash buffer (residual
unreacted DNA) but a strong band was seen in elution buffer indicating near perfect efficiency of
coupling protocol.
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Figure 3.3DNA and Glycan- DNA Conjugate IP Analysis
3.4

qPCR Reactions and Standard Curve
The success of DEGL lies in the readiness of applying the DNA codes to the standard PCR

and qPCR protocols. It is important to have the glycan-coupled DNA (G+DNA) achieve similar
PCR efficiency to the native DNA, so compared the G+DNA conjugates with the corresponding
DNA strands to verify the efficiency of amplification in both PCR and qPCR. In all the above
sections, PCR was performed on the both DNA and G+DNA using standard thermocycling with
different annealing temperatures and Immunoprecipitation methods. Next, experiment was carried
out to determine the qPCR detection limit of both pure DNA and G+DNA. Both pure DNA and
G+DNA were serially diluted to provide different concentrations of templates, with final
concentrations ranging from 2.4 nM to 16 pM. Standard curve qPCR was carried out to obtain the
corresponding Ct values, Critical threshold value (Ct) is generally used to compare the
concentration of the templates in the qPCR reaction mixture, a low Ct indicating high template
concentration. Ct values of the conjugates from 2.4 nM to 16 pM concentrations were observed in
the range of 5-25, while the negative control (no template control, NTC) gave a Ct value above 30
(Figure 3.4). The test was not conducted for further low concentrations worrying about the
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interference of primer dimer formation, a potential challenge in amplifying templates smaller than
100 bases. Nevertheless, a standard plot of the Ct value vs log concentration of the DNA and
G+DNA conjugate (Figure 3.5) did show the linear relation indicating the successful application
of G+DNA for quantitative detection up to the picomolar level. Both DNA and DNA-Glycan
conjugates gave similar amplification, assuring that the DNA tag can be an alternative to detect
the glycan itself. Encouraged by the result clearly suggesting the detection of glycans from even a
picomolar level, proceeded to the final goal, screening of glycans against glycan binding proteins.

Figure 3.4 qPCR limit of detection comparison of glycan DNA conjugate and pure DNA
A &C amplification plot and Ct value plot of glycan DNA conjugate; B & D amplification plot and Ct value
plot of pure DNA
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Figure 3.5 Standard Curve Plot
A) Standard Curve plot of pure DNA; B) Standard Curve plot of Glycan DNA conjugate

3.5

Blood Glycan – Antibody Sensitivity study: Filtration
Since G+DNA could be applied in both screening and detection, DEGLs enable

interrogation of the glycans against target proteins in solution, while known glycan-DNA
interactions could be used to detect a specific target with high sensitivity. Two set of experiments
were done for validating these two aspects of DEGL; initially demonstrated the detection of
specific glycan binding proteins by using the familiar blood glycan-antibody interactions. As a
proof of principle study to demonstrate the significance of DNA Encoded Glycan Library (DEGL),
the blood group antigen-antibody interactions were chosen.
Structures of the O (or H), A, and B antigens are well known (Figure 3.6). This system
was selected for the study mainly due to two reasons, i) It is most studied and accepted among all
the glycan interactions, and ii) They offer the opportunity to study both the sensitivity and
specificity of the technique because of the structural similarities. Three blood group antigens A, B
and O sugars were synthesized chemo-enzymatically. Synthesis of glycan-DNA conjugate was
achieved via click chemistry.44 A, B and O glycans were coupled with the corresponding 5’ alkyne
modified DNA (DNA code + Primers).
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Figure 3.6 Blood Group ABO antigen- DNA conjugate structures
All three G-DNA conjugates (G1+A DNA, G2+B DNA and G3+O DNA, with G1, G2 and
G3 representing A, B, and O glycan antigens, respectively) were interrogated with the
commercially-procured human blood antibodies (IgM, mouse). Concentrations of 5 µM, 2.5 µM,
and 1 µM of the G+DNA were incubated with 2 µL of the antibodies; unbound DNA was
eliminated by filtration with 100k cut off centrifuge tubes. The filtrate after incubating with the
antibodies were subjected to qPCR assay, and Ct values of the G+DNA were compared with the
Ct values of negative control where antibody was omitted from the incubation. A Ct difference of
more than 10 points was observed at all three G+DNA concentrations indicating the requirement
of low concentration of glycans for the accurate results. The filtration results were consistent with
the concentration of antigens used, and were found to be more sensitive (Figure 3.7). The higher
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sensitivity of the filtration method may have been due to the size difference of IgM antibodies and
DNA strands (900 kDa and 25 kDa, respectively). From the above experiment, it was proven that
DEGL can be used for detection of specific glycan binding proteins by using the familiar blood
glycan-antibody interactions over a range of concentration (5 µM, 2.5 µM, 1 µM). With the success
of above experiment, 2.5 µM was used for further demonstration of selectivity and specificity of
the glycan binding proteins by using blood glycan-antibody interactions.
Next aspect of DEGL is to screen for the glycan binding proteins and, for addressing this
mixed all three antibodies (1:1:1) and interrogated this mixture with each of the G+DNA
conjugates (2.5 uM) separately.
As seen in figure 3.8a, Ct values of 8.4 and 7.7 respectively for G1+A DNA and G2+B
DNA indicate the high affinity binding of A and B glycans with their corresponding antibodies
Ab-A and Ab-B. But a similarly tested G3+O DNA showed relatively higher Ct value compared
to both A and B conjugates but still less than that of the no antibody controls indicating weak
interaction of antigens with the Ab-O.
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Figure 3.7 Comparison of Filtration
Sensitivity Study A) G1+A DNA against the antibody A at different concentrations (5 µM, 2.5 µM, 1 µM);
B) G2+B DNA against the antibody B at different concentrations (5 µM, 2.5 µM, 1 µM); C) G3+O DNA
against the antibody O at different concentrations (5 µM, 2.5 µM, 1 µM); D) Ct values plot for G+DNA at
different concentrations (5 µM, 2.5 µM, 1 µM).
This result indicates that DEGL could also work with many closely related target proteins
around without any loss of selectivity. The specificity of the method was also tested, for this
investigated a single G+DNA (G2+B DNA) against the three antibodies, a clear amplification was
visible only when both Ab B and G2+B DNA were in the mix and all the remaining tests were
poorly amplified. This result clearly indicates that the amplification is indeed from the target
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specific binding of glycan and there is no significant interference of nonspecific binding of DNA
and target proteins.

Figure 3.8 Filtration study with G+DNA conjugates and Antibody
A) G+DNA conjugates against the mixture of antibodies having equal concentration of Ab-A, Ab-B and
Ab-O B) G2+B DNA against each antibody separately
3.6

Blood Glycan – Antibody Interaction Comparison: Filtration and
Immunoprecipitation
The next step was to try with natural blood serum, for this blood was collected using finger

pricking as stated in blood collection (under experimental section). Since the natural blood has IgG
antibodies, a comparison between filtration and immunoprecipitation was conducted to find the
best method. For interrogating this aspect G+DNA at concentration of 2.5 µM was incubated with
2 µl of diluted plasma (2 µl of plasma was diluted with 8 µl water) with two different blood plasma
(Blood Groups O and B). The unbound DNA was washed by both filtration and
immunoprecipitation methods. The filtrate/eluent after incubating with the blood plasma (washed
of unbound DNA) were subjected to qPCR assay, and Ct values of the G+DNA were compared
with the Ct values of negative control where blood plasma was omitted from the incubation. A Ct
difference of more than 10 points was observed at filtration results. The filtration results were
consistent with the concentration of antigen used (figure 3.7), and were found to be more sensitive.
The higher sensitivity of the filtration method may have been due to the size difference of IgM
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antibodies and DNA strands (150 kDa and 25 kDa, respectively). A Ct difference of about 10
points was observed at immunoprecipitation results. The immunoprecipitation was consistent with
the concentration of antigen used, and was found to be more accurate and specific from the
amplification curve (Figure 3.10). The higher accuracy and specificity of the immunoprecipitation
may have been due to the compatibility of beads with the qPCR. Ct value of 20.3 in G1+A DNA
and 22.2 in G2+B DNA (Immunoprecipitation) and Ct value of 4.5 in G1+A DNA and 6.8 in
G2+B DNA (Filtration) was obtained with blood group B (Figure 3.9).

Figure 3.9 Ct value comparison
A) Ct value comparison Filtration; B) Ct value Comparison Immunoprecipitation
Similarly, Ct value of 17.6 in G1+A DNA and 18.4 in G2+ B DNA (Immunoprecipitation)
and Ct value of 4.9 in G1+A DNA and 4.8 in G2+B DNA (Filtration) was obtained with blood
group O. A lower Ct value in G1+ A DNA with Blood Group B and almost same Ct value in G1+A
DNA and G2+B DNA with Blood Group O proved this method can be used for inverse blood
group typing.
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Figure 3.10 Amplification plot comparison
A) Amplification Plot Blood Group B Immunoprecipitation; B) Amplification Plot Blood Group O
Immunoprecipitation; C) Amplification Plot Blood Group B Filtration; D) Amplification Plot Blood Group
O Filtration.
3.7

DEGL: Real Life experiments – Inverse Blood Typing
From the successful results with two real blood experiments, blood typing experiments

were conducted by collecting samples from healthy volunteers. Identifying the serum antibody
present in the blood plasma will help to identify the blood group, person having the A antibodies
alone in the blood have B antigen (group B), person with B antibodies alone are of A blood group,
those who have both the antibodies belongs to the O and no antibodies in the blood indicating AB
group (Table 3.2). This type of blood typing is called as inverse blood typing. However, the
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conventional blood typing used widely is based on agglutination which is a direct blood typing
using antigens (glycan antigen) on the surface of the RBC’s.
Table 3.2 Blood Group Antigens and Antibodies

RBC of different
blood group

Antibodies in
Plasma
DEGL
(G1+A DNA,
G2+B DNA)
Results (Ct
values)

Few microliters of blood were collected from 10 healthy volunteers using a finger prick,
collected blood were centrifuged to separate the plasma and cellular components. The blood
plasma was used to detect the blood group, 4 uL of the plasma was diluted to 20 uL and from this
2 uL each was incubated with A and B antibodies for 2 hours to allow the formation of G+DNAAb complexes. Further, G+DNA-Ab complexes were allowed to interact with the protein A/G
magnetic beads for 1 hour, separated using a magnetic stand and washed seven times to discard
any unbound G+DNA. After thoroughly washing the G+DNA-Ab-Bead complex, it was diluted
to 10 uL with water and 1 uL was directly used as a template in the qPCR. Ct values of the G+DNA
in the blood plasma was compared with the Ct value of G+DNA with no plasma. Among the 10
samples tested, two samples showed low Ct values for both G1+A DNA and G2+B DNA
indicating the presence of both antibodies and hence belonged to O group. Five of the samples had
a low Ct value for G2+B DNA means A group and three of the samples had a low Ct value for the
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G1+A DNA implying B group (Figure 3.11). All the results were accorded with the conventional
blood typing. The above results indicated that the DEGL can be used for inverse blood typing,
which can be an alternative for conventional blood typing. However, using this method the rhesus
group cannot be diagnosed as it is a protein antigen-antibody interaction.
No Ab
A

B

O

Figure 3.11 Amplification plot and Ct Value comparison of Blood Typing
3.8

Globo Series Library
After the successful completion of library synthesis and qPCR method development using

blood glycans and inverse blood typing, next the concept was applied to Globo glycans. Here
DEGL and glyco-PCR were used to profile the Globo-glycan binding antibodies and there by
detecting the cancers expressing these antigens. Globo-glycans are part of the glycosphingolipids
and their expression pattern is well correlated with the cancer metastasis and progression. Aberrant
expression of Globo-glycans will also prompt the body to generate the anti-glycan antibodies
targeting these epitopes. These antibodies are generally observed in the sera even before the cancer
progression to the late stages and effectively act as biomarkers for certain types of cancer including
breast, lung, prostate and ovarian cancer.7,36,45
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Figure 3.12 Globo glycan structures and Globo-glycan conjugates
Globo-H and its truncated analogs Gb-5, Gb-4, Gb-3, and Gb-2 were synthesized from the
enzymatic extension of chemically synthesized Gb-2. To test the terminal epitope specificity alone;
Bb-4, Bb-3 and Bb-2 were also synthesized via chemo-enzymatic strategy.
Initially, tested with the Globo-H glycan conjugate alone with the commercial anti GloboH human antibody VK-9 in the same way as with the blood glycans, and the results are shown in
the figure 3.13. Two concentrations of Globo-H glycan-DNA conjugate (2.5 µM and 5 µM) were
incubated with 2 µL of VK-9 antibody and compared the Ct value with the no antibody control
experiments. As expected, the amplification and Ct values were correlated with the concentration
of the antigens present in the solution, a low Ct value of 7 and 19 was observed for 5 µM conjugate
and comparatively higher Ct value of 14 and 21 was obtained for 2.5 µM conjugate.
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Figure 3.13 Amplification plot and Ct value Globo-H Vs VK-9 A) Amplification Plot and B) Ct Value
plot

3.9

Detection of glycan binding antibodies present in the cancer plasma
After gaining the confidence from the Globo-H and VK-9 interrogation studies, we

conducted an elaborate study using all the Globo series glycan against two breast cancer plasma
samples (sanguine bioscience BC1 and BC2), and compared the Ct values of each glycan
conjugates with the sample treated with both healthy serum (HS) and no serum (NS). The results
show that only GbH, Bb4 and Bb3 had significant amplification with the Ct values less than 8,
while other glycan conjugates show relatively less amplification (Figure 3.14 and 3.15).
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Globo-H Glycan Vs Cancer Plasma
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Figure 3.14 Ct Value Plot of different Globo glycan conjugate series with breast cancer serum (BC1 and
BC2), Healthy Serum (HS) and No Serum (NS).

These results are consistent with the micro array based methods reported by Chi-Huey
Wong group.7 Though this approach accurately differentiated the cancer plasma from the healthy
plasma based on the presence of glycan binding antibodies, it is not convenient to test every glycan
conjugate separately and it is not practical when several plasma samples are needed to be tested.
But this difficulty can be easily overcome by employing next generation sequencing (NGS), which
allow mixing of the glycan conjugate and mixing of plasma samples with one additional step of
barcode indexing. Hence NGS technology allows the high throughput detection of hundreds of
plasma samples with even thousands of glycans in the DEGL.
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Figure 3.15 Amplification Plot of different Globo glycan conjugate series with breast cancer serum
(BC1 and BC2), Healthy serum (HS) and No serum (NS)
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4

CONCLUSION

With the advancement of the technologies in the DNA synthesis and sequencing have
brought the enormous potential of DNA in the applications beyond genetics. DNA encoded
libraries (DEL) are of the modern concept in drug screening and lead optimization. This study
recognized the importance of DEL technologies in the functional glycomics (DEGL), which is
otherwise limited to the low sensitive detection techniques and highly difficult to obtain samples.
Applying the highly sensitive qPCR detection will enhance the reach of functional glycomics to
low nano gram samples and high throughput screening. Here a unique method has been described
to code each glycan, accounting their structural information very similar to how proteins coded
with triplet codons. The program which is available for the use of research community is aimed to
provide and keep a uniformity in the codes for every single glycan in the future DEGL
technologies.
A strict library of DNA codes will not only reduce the confusion in the community but also
bring down the synthetic expenses using optional bulk synthesis. Along with the unique DNA
codes, it also produces an agreement on the coupling chemistry and primer selection to have the
ready-made glycan codes for research use. Also identified copper assisted alkyne-azide coupling
(CuAAC) chemistry, also known as ‘click chemistry’ for the best result in because most DNA
suppliers readily offer azide and alkyne modifications on their library.
In a proof of principle study, generated a small DEGL consisting the common blood
antigens and their detection in solution were demonstrated. With the same principle did a blood
group analysis with the DEGL to confirm the use of DEGL in detecting the glycan binding
antibodies. Although inverse blood typing can’t replace the gold standard conventional direct
blood typing based on the surface antigen, this study can be further extended to the next level
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where the blood typing will be based on the analysis of P1PK, FORS, Se, Le and I blood glycan
antigens. All the blood glycan antigens (ABO, P1PK, FORS, Se, Le and I) will form a complete
blood glycan group typing. Some of them being highly rare antigens, this kind of analysis will
make a place along with molecular blood typing and other rare antigen blood typing apart from
the conventional ABO typing.
Finally, another DEGL consisting the Globo glycan series was generated and their
detection in solution and breast cancer serum were demonstrated to confirm the use of DEGL in
detecting the glycan binding antibodies which are of highly significant in the diagnostic
applications. Here, Globo-glycans were analyzed in cancer serum which can be extended to several
other diseases like Crohn’s disease, Rheumatoid arthritis, cancers and infection where diseasespecific glycan biomarkers and determinants can be found. This application of DEGL can be
promising for the analysis of disease-specific glycan biomarkers and determinants for early
diagnosis of the disease.
With the successful results from the proof of principle study namely inverse blood typing
and detection of Globo-glycans in cancer samples, it has been proven that the DEGL will be an
efficient method in future years to come. DEGL will find its own space along with other prevalent
technologies available.
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